ES2145355T3 - 4h-piranos sustituidos con actividad moduladora sobre los canales de potasio. - Google Patents

4h-piranos sustituidos con actividad moduladora sobre los canales de potasio.

Info

Publication number
ES2145355T3
ES2145355T3 ES96112427T ES96112427T ES2145355T3 ES 2145355 T3 ES2145355 T3 ES 2145355T3 ES 96112427 T ES96112427 T ES 96112427T ES 96112427 T ES96112427 T ES 96112427T ES 2145355 T3 ES2145355 T3 ES 2145355T3
Authority
ES
Spain
Prior art keywords
pyranes
replaced
potassium channels
modulating activity
sup
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96112427T
Other languages
English (en)
Inventor
Klaus Dr Urbahns
Hans-Georg Dr Heine
Bodo Dr Junge
Frank Dr Mauler
Thomas Dr Glaser
Reilinde Dr Wittka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2145355T3 publication Critical patent/ES2145355T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

LA 4H-PIRANOS SUSTITUIDOS DE FORMULA (I) SE OBTIENEN O POR REACCION DE ALDEHIDOS O DE COMPUESTOS DE ILIDENO CON {BE}DICETONAS CON SUSTITUCIONES ADECUADAS. LOS 4H-PIRANOS SUSTITUIDOS DE LA INVENCION ESTAN INDICADOS COMO PRINCIPIOS ACTIVOS EN MEDICAMENTOS, EN ESPECIAL PARA EL TRATAMIENTO DE ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL. A, R{SUP,1}-R{SUP,4} TIENEN LOS SIGNIFICADOS DADOS EN LA DESCRIPCION.
ES96112427T 1995-08-14 1996-08-01 4h-piranos sustituidos con actividad moduladora sobre los canales de potasio. Expired - Lifetime ES2145355T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19529858A DE19529858A1 (de) 1995-08-14 1995-08-14 Substituierte 4H-Pyrane

Publications (1)

Publication Number Publication Date
ES2145355T3 true ES2145355T3 (es) 2000-07-01

Family

ID=7769442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96112427T Expired - Lifetime ES2145355T3 (es) 1995-08-14 1996-08-01 4h-piranos sustituidos con actividad moduladora sobre los canales de potasio.

Country Status (25)

Country Link
US (1) US5760073A (es)
EP (1) EP0758648B1 (es)
JP (1) JPH0959271A (es)
KR (1) KR970010758A (es)
CN (1) CN1147512A (es)
AT (1) ATE190611T1 (es)
AU (1) AU708956B2 (es)
CA (1) CA2183048A1 (es)
CZ (1) CZ239496A3 (es)
DE (2) DE19529858A1 (es)
DK (1) DK0758648T3 (es)
EE (1) EE9600114A (es)
ES (1) ES2145355T3 (es)
GR (1) GR3033357T3 (es)
HU (1) HUP9602220A3 (es)
IL (1) IL119054A (es)
MX (1) MX9603342A (es)
NO (1) NO963374L (es)
NZ (1) NZ299145A (es)
PL (1) PL315652A1 (es)
PT (1) PT758648E (es)
RU (1) RU2164915C2 (es)
SI (1) SI0758648T1 (es)
SK (1) SK105596A3 (es)
ZA (1) ZA966832B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744259B2 (en) * 1997-04-07 2002-02-21 Gian Luca Araldi Analogs of cocaine
US6221550B1 (en) 2000-03-31 2001-04-24 Nexpress Solutions Llc 4H-pyran charge control agents for electrostatographic toners and developers
WO2009006580A1 (en) * 2007-07-05 2009-01-08 Cv Therapeutics, Inc. Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
JP5120070B2 (ja) * 2008-05-29 2013-01-16 三浦工業株式会社 水処理装置

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235406C3 (de) * 1972-07-19 1982-01-07 Bayer Ag, 5090 Leverkusen 2-Amino-4H-pyrane, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Arzneimittel
DE3208628A1 (de) * 1982-03-10 1983-09-22 Bayer Ag, 5090 Leverkusen Neue verbindungen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel

Also Published As

Publication number Publication date
IL119054A (en) 2000-10-31
MX9603342A (es) 1997-03-29
HUP9602220A2 (en) 1997-05-28
DK0758648T3 (da) 2000-07-24
PT758648E (pt) 2000-08-31
PL315652A1 (en) 1997-02-17
KR970010758A (ko) 1997-03-27
SI0758648T1 (en) 2000-06-30
RU2164915C2 (ru) 2001-04-10
JPH0959271A (ja) 1997-03-04
HUP9602220A3 (en) 1998-04-28
CA2183048A1 (en) 1997-02-15
AU708956B2 (en) 1999-08-19
DE19529858A1 (de) 1997-02-20
IL119054A0 (en) 1996-11-14
ATE190611T1 (de) 2000-04-15
NO963374L (no) 1997-02-17
NO963374D0 (no) 1996-08-13
EP0758648B1 (de) 2000-03-15
SK105596A3 (en) 1997-03-05
EE9600114A (et) 1997-02-17
EP0758648A1 (de) 1997-02-19
CN1147512A (zh) 1997-04-16
GR3033357T3 (en) 2000-09-29
DE59604649D1 (de) 2000-04-20
NZ299145A (en) 1998-03-25
ZA966832B (en) 1997-02-20
HU9602220D0 (en) 1996-10-28
CZ239496A3 (en) 1997-03-12
AU6193196A (en) 1997-02-20
US5760073A (en) 1998-06-02

Similar Documents

Publication Publication Date Title
ATE336229T1 (de) Zusammensetzung auf der basis polymerer mizellen
PT94568A (pt) Quinazolinonas substituidas como antagonistas da angiotensina ii
BR0313676A (pt) Derivados de pirimidina e uso destes como moduladores cb2
ES2194918T3 (es) Compuestos de tiazol y tiadiazol como ligando receptor de dopamina d3.
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
ES2181130T3 (es) Antagonistas quinazolin-4-ona del ampa.
ES2184070T3 (es) Derivados de oximas sustituidas utiles como antagonistas de la neuroquinina.
ES2092113T3 (es) Derivados fluoroalcoxibencilamino de heterociclos que contienen nitrogeno.
BR9701248A (pt) Novos pró-medicamentos para a terapia de tumores e distúrbios inflamatórios
ES2195189T3 (es) Benzonaftiridinas como agentes terapeuticos bronquiales.
NO974321L (no) Nodulisporsyrederivater
ATE368023T1 (de) Hydroxydiphenyletherverbindungen
ES2178761T3 (es) Utilizacion de 1-hidroxi-2-piridonas para el tratamiento de infe cciones cutaneas.
PT971922E (pt) Compostos de tetra-hidropirido
ES2145355T3 (es) 4h-piranos sustituidos con actividad moduladora sobre los canales de potasio.
ES2166899T3 (es) Derivados de acido fenilacetico, procedimiento y productos intermedios para su obtencion, y su empleo como parasiticida y fungicida.
MX9305093A (es) Nuevos derivadosindano-2 mercaptoacetilamina triciclicos 2-sustituidos, utiles como inhibidores de la encefalinasa.
TR199901017A2 (xx) B�cek ilac� terkibi.
ES2059457T3 (es) Utilizacion de bezafibrato para el tratamiento de la diabetes.
UY26265A1 (es) Compuestos calciolíticos
ES2130506T3 (es) Uso de 5-acil-1,4-dihidropiridinas para tratamiento de enfermedades del snc.
ES2156319T3 (es) Derivados de 10,11-dihidro-10-oxo-5h-dibenz/b,f/azepin-5-carboxamida.
ES2154692T3 (es) Dihidrofarnesal.
ES2157419T3 (es) Arilazadioxacicloalquenos substituidos, fungicidas.
BR0016781A (pt) Bases de 1-naftol e 2-naftol - mannich substituìdas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 758648

Country of ref document: ES